|
|
|
Drug Delivery Leader Executive Editor Fran DeGrazio welcomed quality and risk management experts Laurie Auerbach and Edwin Bills in a discussion of the history and intentions of the new QMSR and what it means for combination product manufacturers. They highlighted specific areas of risk that your organization may need to address. Drug Delivery Leader Chief Editor and Community Director Tom von Gunden was on hand to provide an overarching framing of the topics within the context of the new QMSR. |
|
|
|
|
| The Impact Of PFAS Regulations On Drug Delivery Devices | Article | By Shalene Thomas, Battelle | By adopting a strategic approach and embracing necessary measures, the medical device industry can transform regulatory challenges surrounding PFAS into opportunities for innovation and growth. |
|
|
| Combining Gene Therapies, Carrier Systems, And Medical Devices | Article | By Stefanie Johns, Ph.D., Kymanox Corporation | Drug delivery is one of the most significant obstacles to advancing gene therapies. Examine the opportunities for success in combining novel medical devices to improve delivery of gene therapies. |
|
|
|
|
|
|
|
|
|
|
.png){kind=logo}
